Seagen Digs Deep For Lava’s Bispecific Antibody

 
• By Alaric DeArment
Seagen and Lava signed a licensing deal for Lava's preclinical bispecific antibody candidate, LAVA-1223 • Source: Shutterstock

More from Deals

More from Business